No Data
Peering Into Editas Medicine's Recent Short Interest
Editas Medicine to Announce Fourth Quarter/Full Year 2024 Financial Results and to Participate in Investor Conferences in March
$EDIT Stock Is up 17% Today. Here's What We See in Our Data.
BofA Securities Maintains Editas Medicine(EDIT.US) With Sell Rating, Announces Target Price $1
Editas Medicine: Strategic Ambitions and Cautious Optimism in Gene-Editing Advancements
Wells Fargo Maintains Editas Medicine(EDIT.US) With Hold Rating, Cuts Target Price to $3
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}